Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 7, 2024 -- For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product, lisocabtagene maraleucel (liso-cel), is safe for outpatients and inpatients and is efficacious, according to a study published online Sept. 30 in Blood Advances.
Yuliya Linhares, M.D., from the Miami Cancer Institute, and colleagues examined outpatient safety and efficacy following liso-cel treatment at community sites in the United States among adults with relapsed/refractory LBCL after two or more prior lines of therapy. Eighty-two patients received liso-cel (70 percent outpatient-monitored; 30 percent inpatient-monitored) and were followed for a median of 10.6 months.
The researchers found that grade 3 or higher cytokine release syndrome occurred in 0 and 0 percent of outpatients and inpatients, respectively; neurological events occurred in 12 and 4 percent; infections in 12 and 8 percent; and prolonged cytopenia in 33 and 32 percent. Twenty-five percent of outpatients were never hospitalized after infusion and 32 percent were hospitalized within 72 hours after the day of infusion; the median time to hospitalization was 5.0 days. After liso-cel, median initial hospitalization duration was 6.0 and 15.0 days for outpatients and inpatients, respectively. The objective response rate and complete response rate were 80 and 54 percent, respectively; the median duration of response was 14.75 months.
"These findings support liso-cel treatment at community medical centers using standard operating procedures and multidisciplinary teams with outpatient monitoring in appropriate patients," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Bristol Myers Squibb, which manufactures liso-cel and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos
FRIDAY, March 7, 2025 -- Tattooed individuals have an increased risk for lymphoma and skin cancers, according to a study recently published in BMC Public Health. Signe Bedsted...
Obesity at Pediatric Cancer Diagnosis Linked to Inferior Survival
MONDAY, Jan. 13, 2025 -- Obesity at cancer diagnosis is associated with inferior survival among children aged 2 to 18 years, according to a study published online Jan. 13 in...
Position Statement Developed for Managing Blood Cancers in Pregnancy
WEDNESDAY, Jan. 8, 2025 -- In a new position statement published online Jan. 3 in The Lancet Haematology, guidelines are presented for the management of acute leukemia and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.